Adjuvant and neoadjuvant therapy for gastric cancer

被引：21
作者：
Gonzalez, RJ [1 ]
Mansfield, PF [1 ]
机构：
[1] Univ Texas, MD Anderson Canc Ctr, Dept Surg Oncol, Unit 444, Houston, TX 77030 USA
来源：
SURGICAL CLINICS OF NORTH AMERICA | 2005年 / 85卷 / 05期
关键词：
D O I：
10.1016/j.suc.2005.05.004
中图分类号：
R61 [外科手术学];
学科分类号：
摘要：
Although the incidence of gastric cancer is decreasing, it remains a significant source of cancer-related mortality. Surgery remains the best chance for cure from gastric cancer. Adjuvant and neoadjuvant therapy have played increasing roles in attempting to reduce the disease-specific mortality and prolong survival. In this article, the authors review the literature and summarize the salient points regarding the roles of adjuvant and neoadjuvant therapy for gastric cancer.
引用
收藏
页码：1033 / +
页数：20
相关论文
共 89 条
[1]   Multi-institutional trial of preoperative chemoradiotherapy in patients with potentially resectable gastric carcinoma [J].
Ajani, JA ;
Mansfield, PF ;
Janjan, N ;
Morris, J ;
Pisters, PW ;
Lynch, PM ;
Feig, B ;
Myerson, R ;
Nivers, R ;
Cohen, DS ;
Gunderson, LL .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) :2774-2780
[2]   Enhanced staging and all chemotherapy preoperatively in patients with potentially resectable gastric carcinoma [J].
Ajani, JA ;
Mansfield, PF ;
Lynch, PM ;
Pisters, PW ;
Feig, B ;
Dumas, P ;
Evans, DB ;
Raijman, I ;
Hargraves, K ;
Curley, S ;
Ota, DM .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (08) :2403-2411
[3]  
AJANI JA, 1991, CANCER-AM CANCER SOC, V68, P1501, DOI 10.1002/1097-0142(19911001)68:7<1501::AID-CNCR2820680706>3.0.CO
[4]  
2-L
[5]   PREOPERATIVE AND POSTOPERATIVE COMBINATION CHEMOTHERAPY FOR POTENTIALLY RESECTABLE GASTRIC-CARCINOMA [J].
AJANI, JA ;
MAYER, RJ ;
OTA, DM ;
STEELE, GD ;
EVANS, D ;
ROH, M ;
SUGARBAKER, DJ ;
DUMAS, P ;
GRAY, C ;
VENA, DA ;
STABLEIN, DM .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1993, 85 (22) :1839-1844
[6]  
ALLUM W, 2003, P AN M AM SOC CLIN, V22, P249
[7]  
ALLUM WH, 1989, LANCET, V1, P571
[8]   Long-term follow-up of a pilot phase II study with neoadjuvant epidoxorubicin, etoposide and cisplatin in gastric cancer [J].
Barone, C ;
Cassano, A ;
Pozzo, C ;
D'Ugo, D ;
Schinzari, G ;
Persiani, R ;
Basso, M ;
Brunetti, IM ;
Longo, R ;
Picciocchi, A .
ONCOLOGY, 2004, 67 (01) :48-53
[9]  
BONFANTI G, 1988, BRIT J SURG, V75, P1100
[10]  
CARRATO A, 1995, P AN M AM SOC CLIN, pA468
123456789